CS-801 phase 3 long-term study
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sankyo
- 10 Jun 2016 New trial record
Latest Information Update: 10 Jun 2016